Skip to content

US · DMRA · BIOTECHNOLOGY

Damora Therapeutics, Inc. (DMRA) intrinsic value and stock valuation

$23.22as of 2026-11-21 · Mkt cap 1.9B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Damora Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DMRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DMRA’s statements →

Damora Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02453 damoratx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-209.84M
20182025
Free cash flow
-$-6.73M
20182025
Total equity
$240.4M+7.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-210.87M-$-16.9M-$-36.46M-$-61.21M-$-52.23M
Net income-$-209.84M-$-21.44M-$-38.35M-$-61.62M-$-51.75M
EPSd-$-153.17M-$-18.48M-$-36.18M-$-60.41M-$-51.24M
Operating cash flow-$-6.73M-$-18.62M-$-36.91M-$-42.93M-$-52.31M
Capital expenditure$0.00$0.00$0.00-$-200K-$-220K
Free cash flow-$-6.73M-$-18.62M-$-36.91M-$-43.13M-$-52.53M
Total assets$260.5M$17.1M$38.2M$73.2M$122.2M
Total debt$70K$1.43M$250K$800K$850K
Net debt-$-257.56M-$-12.74M-$-21.22M-$-31.98M-$-61.72M
Total equity$240.4M$14.5M$32.3M$61.8M$117.2M
Cash and short-term investments$257.6M$14.2M$33.2M$60.2M$100.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$180K$830K$490K$440K
Gross profit$0.00-$-180K-$-830K-$-490K-$-440K
Research and development expenses$201.2M$6.4M$23.8M$48.2M$38.5M
Selling, general and administrative expenses$9.69M$10.3M$11.9M$12.5M$13.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$210.9M$16.7M$35.6M$60.7M$51.8M
Cost and expenses$210.9M$16.9M$36.5M$61.2M$52.2M
Interest income$1.17M$840K$1.69M$720K$160K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$30K$180K$830K$490K$440K
Ebitda-$-209.75M-$-21.22M-$-37.52M-$-61.13M-$-51.31M
Operating income-$-210.87M-$-16.9M-$-36.46M-$-61.21M-$-52.23M
Total other income/expenses, net$1.08M-$-4.5M-$-1.89M-$-420K$470K
Income before tax-$-209.79M-$-21.4M-$-38.35M-$-61.62M-$-51.75M
Income tax expense$50K$40K$0.00$0.00$0.00
Net income-$-209.84M-$-21.44M-$-38.35M-$-61.62M-$-51.75M
Weighted average shares outstanding$1.37M$1.16M$1.06M$1.02M$1.01M
Weighted average diluted shares outstanding$1.37M$1.16M$1.06M$1.02M$1.01M
Balance sheet
20252024202320222021
Cash and short-term investments$257.6M$14.2M$33.2M$60.2M$100.2M
Net receivables$900K$880K$1.72M$1.38M$2.28M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$260.4M$16.8M$36.8M$63.9M$110.1M
Property, plant and equipment, net$100K$130K$330K$1.17M$1.04M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$5.83M$9.05M
Total non-current assets$100K$290K$1.45M$9.28M$12.1M
Total assets$260.5M$17.1M$38.2M$73.2M$122.2M
Accounts payable$440K$380K$1.7M$3.35M$1.53M
Short-term debt$10K$10K$180K$480K$400K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.1M$1.2M$5.83M$11.1M$4.54M
Long-term debt$50K$1.42M$70K$330K$450K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$1.46M$70K$330K$450K
Capital lease obligations$70K$60K$70K$330K$450K
Total liabilities$20.2M$2.66M$5.9M$11.4M$4.99M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-487.36M-$-277.52M-$-256.08M-$-217.74M-$-156.11M
Accumulated other comprehensive income (loss)$800K$100K$380K-$-240K-$-320K
Total equity$240.4M$14.5M$32.3M$61.8M$117.2M
Total investments$0.00$0.00$11.7M$33.3M$46.7M
Total debt$70K$1.43M$250K$800K$850K
Net debt-$-257.56M-$-12.74M-$-21.22M-$-31.98M-$-61.72M
Cash flow statement
20252024202320222021
Net income-$-209.84M-$-21.44M-$-38.35M-$-61.62M-$-51.75M
Depreciation and amortization$30K$180K$830K$490K$440K
Stock-based compensation$1M$0.00$0.00$0.00$0.00
Change in working capital$18.4M-$-2.67M-$-4.37M$11.9M-$-6.62M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$17.3M-$-1.32M-$-1.65M$1.82M-$-1.32M
Net cash provided by operating activities-$-6.73M-$-18.62M-$-36.91M-$-42.93M-$-52.31M
Investments in property, plant and equipment$0.00$0.00$0.00-$-200K-$-220K
Acquisitions, net-$-17.37M$0.00$80K$0.00$0.00
Net cash used for investing activities-$-17.37M$11.7M$22.3M$12.4M-$-48.05M
Common stock issued$0.00$0.00$2.88M$510K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$266.8M$0.00$2.88M$510K$0.00
Net change in cash$243.5M-$-7.29M-$-11.32M-$-29.78M-$-101.02M
Cash at end of period$257.6M$14.2M$21.5M$32.8M$62.6M
Operating cash flow-$-6.73M-$-18.62M-$-36.91M-$-42.93M-$-52.31M
Capital expenditure$0.00$0.00$0.00-$-200K-$-220K
Free cash flow-$-6.73M-$-18.62M-$-36.91M-$-43.13M-$-52.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Damora Therapeutics, Inc.

        Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

        CEO
        Jennifer A. Jarrett
        Employees
        7
        Beta
        1.47

        Explore

        Frequently asked questions

        What is the intrinsic value of Damora Therapeutics, Inc. (DMRA)?

        InvestorsCraft does not currently publish an intrinsic value for DMRA. How the IC value is calculated.

        Is DMRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for DMRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.